AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Pharmacodynamic Study With Ticagrelor in African American Patients
Phase 4
Completed
- Conditions
- Stable Coronary Artery Disease
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2014-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT01523392
- Locations
- 🇺🇸
Research Site, Beaumont, Texas, United States
A Pharmacodynamic Study With Ticagrelor in Hispanic Patients
Phase 4
Completed
- Conditions
- Stable Coronary Artery Disease
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2014-08-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 53
- Registration Number
- NCT01523366
- Locations
- 🇺🇸
Research Site, Linden, New Jersey, United States
A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM
Completed
- Conditions
- Type II Diabetes Mellitus
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4911
- Registration Number
- NCT01523405
- Locations
- 🇮🇳
Research Site, New Delhi, India
Metoprolol in Acute Myocardial Infarction. A PK/PD Study
Phase 1
Completed
- Conditions
- Acute Myocardial Infarction
- Interventions
- Drug: Metoprolol- LopressorDrug: Metoprolol- Toprol XL
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT01523054
Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118
Phase 1
Completed
- Conditions
- Drug- Drug InteractionsBioavailabilityHealthy Volunteers
- Interventions
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT01520896
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI)
Completed
- Conditions
- Rheumatoid ArthritisAnkylosing SpondylitisOsteoarthritis
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2012-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT01519375
- Locations
- 🇸🇪
Research Site, Vannas, Sweden
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
Phase 3
Completed
- Conditions
- Crohn's Disease
- Interventions
- Drug: D9421-C capsule 3 mg
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 123
- Registration Number
- NCT01514240
- Locations
- 🇯🇵
Research Site, Toyota-shi, Japan
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
Completed
- Conditions
- OsteoarthritisAnkylosing SpondylitisRheumatoid Arthritis
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT01511926
- Locations
- 🇬🇧
Research Site, Warminster, United Kingdom
Assessment of MDD Management in Andalusia
Completed
- Conditions
- MDD Management Strategies
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5309
- Registration Number
- NCT01510886
- Locations
- 🇪🇸
Research Site, Granada, Spain
Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- COPDChronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-01-13
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 158
- Registration Number
- NCT01509677